(Q36269608)

13 August 2017

1 reference

title

Variability factors in the clinical response to recombinant antibodies and IgG Fc-containing fusion proteins (English)

1 reference

13 August 2017

Hervé Watier

1

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 September 2005

1 reference

Expert Opinion on Biological Therapy

13 August 2017

published in

1 reference

13 August 2017

volume

5 Suppl 1

1 reference

13 August 2017

page(s)

S29-36

1 reference

Therapeutic antibodies for human diseases at the dawn of the twenty-first century

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S29

Monoclonal antibodies market

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S29

The pharmacological basis of anti-IgE therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S29

Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S29

Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S29

Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S29

Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S29

The effect of HLA–DR on susceptibility to rheumatoid arthritis is influenced by the associated lymphotoxin α–tumor necrosis factor haplotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S29

Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S29

Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S29

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S29

Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S29

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S29

The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S29

Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S29

FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S29

FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S29

A single recombinant anti-RhD IgG prevents RhD immunization: association of RhD-positive red blood cell clearance rate with polymorphisms in the FcgammaRIIA and FcgammaIIIA genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S29

Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S29

Life and death in the gut: more killing, less Crohn's

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S29

A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S29

Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S29

Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S29

Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S29

The immunogenicity of chimeric antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S29

High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S29

Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S29

Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S29

Therapeutic monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S29

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S29

21 January 2018

Identifiers

DOI

10.1517/14712598.5.1.S29

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/5wqepsqk6fejpozu2tfiqairv4

mapped directly with Wikidata item

30 July 2022

based on heuristic

Fatcat ID

release_5wqepsqk6fejpozu2tfiqairv4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/5wqepsqk6fejpozu2tfiqairv4

mapped directly with Wikidata item

30 July 2022

based on heuristic

https://api.fatcat.wiki/v0/release/5wqepsqk6fejpozu2tfiqairv4

1 reference